Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol-Myers Squibb (NYSE:BMY) posted second-quarter earnings that surpassed analyst expectations, largely thanks to robust ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 9,747 puts trading, or 1.5x expected. Most active are 8/1 weekly 46 ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...